PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that pharmacodynamic data from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, have been selected for oral presentation at ESC Congress 2019, being held August 31 – September 4, 2019, at the Expo Porte de Versailles in Paris, France.
Presentation details are as follows:
Title: Evaluation of the Pharmacodynamics of a Ticagrelor Reversal Agent PB2452
Session: New Developments in Anti-Thrombotic Drug Therapy
Date / Time: Sunday, September 1, 17:32 – 17:50 GMT/ 11:32 – 11:50 AM EDT
Location: Reykjavik – Village 2
Presenter: Lisa K. Jennings, Ph.D., University of Tennessee Health Science Center
Session: New Developments in Anti-Thrombotic Drug Therapy
Date / Time: Sunday, September 1, 17:32 – 17:50 GMT/ 11:32 – 11:50 AM EDT
Location: Reykjavik – Village 2
Presenter: Lisa K. Jennings, Ph.D., University of Tennessee Health Science Center
Additional information can be found on the ESC Congress website here.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.